FY2029 Earnings Forecast for AKBA Issued By HC Wainwright

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – HC Wainwright issued their FY2029 earnings per share estimates for Akebia Therapeutics in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will post earnings per share of $2.17 for the year. HC Wainwright currently has a “Buy” rating and a $7.50 target price on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.24) per share.

Separately, StockNews.com lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday.

Akebia Therapeutics Stock Performance

Shares of AKBA stock opened at $1.94 on Thursday. Akebia Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $2.48. The company has a market capitalization of $423.27 million, a P/E ratio of -8.43 and a beta of 0.72. The stock has a 50 day moving average price of $1.90 and a two-hundred day moving average price of $1.56.

Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The company had revenue of $37.43 million during the quarter, compared to the consensus estimate of $45.66 million. During the same period in the previous year, the company earned ($0.08) EPS.

Institutional Trading of Akebia Therapeutics

Several large investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in Akebia Therapeutics by 10.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 98,546 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 9,662 shares during the last quarter. Franklin Resources Inc. purchased a new stake in Akebia Therapeutics in the third quarter worth about $221,000. Barclays PLC lifted its holdings in Akebia Therapeutics by 276.1% in the third quarter. Barclays PLC now owns 273,085 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 200,482 shares during the period. Geode Capital Management LLC boosted its position in Akebia Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 4,754,464 shares of the biopharmaceutical company’s stock valued at $6,277,000 after acquiring an additional 218,172 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Akebia Therapeutics during the 3rd quarter worth approximately $58,000. 33.92% of the stock is owned by institutional investors.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.